Reasons for not seeing drug representatives

Editorial

D Griffith. BMJ. 1999.

. 1999 Jul 10;319(7202):69-70.

doi: 10.1136/bmj.319.7202.69.

No abstract available

Comment in

Reasons for not seeing drug representatives. They should be seen because they are a good resource.
Tiner R. Tiner R. BMJ. 1999 Oct 9;319(7215):1002. BMJ. 1999. PMID: 10514174 Free PMC article. No abstract available.
Reasons for not seeing drug representatives. But doctors do see them: "freebies" seem disproportionately important.
Jacobs A. Jacobs A. BMJ. 1999 Oct 9;319(7215):1002. BMJ. 1999. PMID: 10576839 No abstract available.
Reasons for not seeing drug representatives. Companies have to encourage doctors to prescribe their products.
Dodd P, Dexter T. Dodd P, et al. BMJ. 1999 Oct 9;319(7215):1002-3. BMJ. 1999. PMID: 10576840 No abstract available.
Reasons for not seeing drug representatives. Drug representatives have much to offer.
Benbow AG. Benbow AG. BMJ. 1999 Oct 9;319(7215):1003. BMJ. 1999. PMID: 10576841 No abstract available.

Beyond conflict of interest. Transparency is the key.
Smith R. Smith R. BMJ. 1998 Aug 1;317(7154):291-2. doi: 10.1136/bmj.317.7154.291. BMJ. 1998. PMID: 9685268 Free PMC article. No abstract available.

1. Consultant Physicians Working for Patients. J Roy Coll Phys London. 1998;32 (suppl 1):S1–20. - PMC - PubMed
1. Sidford I. Practice’s consultation rates have increased by three quarters in past 25 years. BMJ. 1997;315:546–547. - PMC - PubMed
1. Lexchin J. Doctors and detailers: therapeutic education or pharmaceutical promotion? Int J Health Services. 1989;19:663–679. - PubMed
1. Lexchin J. Interactions between physicians and the pharmaceutical industry: What does the literature say? Can Med Assoc J. 1993;149:1401–1407. - PMC - PubMed
1. McGavock H, Webb CH, Johnston GD, Milligan E. Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators. BMJ. 1993;307:1118–1120. - PMC - PubMed